Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSynthomer Regulatory News (SYNT)

Share Price Information for Synthomer (SYNT)

Share Price is delayed by 15 minutes
Get Live Data
99.50    -2.30 (-2.26%)
Bid:
99.60
Ask:
100.40
Spread: 0.80 (0.803%)
Market Cap: £163.12m
SYNT Live PriceLast checked at - London Stock Exchange

Intraday Synthomer Share Chart

Interim Management Statement

12 May 2011 07:00

RNS Number : 4433G
Yule Catto & Co PLC
12 May 2011
 



12 May 2011

 

Yule Catto & Co plc (the "Group") 

 

Interim Management Statement

 

At this afternoon's AGM of Yule Catto & Co plc, the international producer of speciality chemicals, Chairman Peter Wood will make the following statement which also comprises the Group's interim management statement for the period 1 January 2011 to date.

 

The Group's earnings for the first quarter were well ahead of the same period last year excluding any impact of the PolymerLatex acquisition, and the Board's expectations for financial performance for 2011 remain unchanged.

 

Overall demand in Yule Catto's Polymer business was solid. Asian demand was strong through the quarter, whilst Europe firmed after a slow start in the UK. Ongoing very substantial monomer price increases have had to be passed on to customers, resulting in the usual temporary margin compression as the increases are recovered and target unit margins per tonne restored. Consequently, although volumes increased in Polymers and turnover was strongly ahead, operating profit was flat year on year in the first quarter. Whilst Europe lagged the prior year, Asia was ahead, despite, as expected, profits being temporarily constrained by capacity during the quarter. This position will be resolved in the course of the second quarter with the new 15,000 tonne nitrile expansion coming on line and some spare capacity in the acquired PolymerLatex nitrile assets. In April, the existing Yule Catto polymer business performed ahead of prior year.

 

The acquisition of PolymerLatex completed at the end of March as anticipated. Integration planning progressed through the first quarter and is now being implemented. Post acquisition, the synergy potential has been confirmed, and management remain highly confident that at least £20m of synergies will be delivered as disclosed at the time of the acquisition announcement and to the same timetable. Regular updates on progress in delivering these synergies will be provided to investors, with the first update to be delivered with the group's half year results in August. As at the date of this statement, actions taken to date have already delivered synergies with an annual run rate value of approximately £2m.

 

PolymerLatex itself traded comfortably ahead of last year in the first quarter, and this has continued through April. The business benefited from good demand in central Europe for latex and volume growth in its Malaysian nitrile facility. Plans are already being developed for very substantial increases in capacity in Asia for nitrile and SBR latex to be brought on line before the end of 2012.

 

In the Group's other businesses in the first quarter, the Pharma division performed well ahead of what was a very weak result in the same period last year, whilst William Blythe continued to grow profits strongly.

 

Net debt at the end of the quarter stood at £235m reflecting the impact of the acquisition of PolymerLatex, in line with the Group's forecasts at the time of the acquisition announcement.

 

- Ends -

 

ENQUIRIES:

 

Yule Catto & Co plc

Tel: 01279 442791

Adrian Whitfield, Chief Executive

David Blackwood, Group Finance Director

MHP Communications

Tel: 020 3128 8100

Andrew Jaques

John Olsen

Ian Payne

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IMSLFFLFERILLIL
Date   Source Headline
13th Jul 201210:38 amRNSChange of Auditor
6th Jul 20129:38 amRNSHolding(s) in Company
3rd Jul 20124:35 pmRNSHolding(s) in Company
2nd Jul 201212:46 pmRNSHolding(s) in Company
2nd Jul 201211:11 amRNSDirector/PDMR Shareholding
27th Jun 20127:00 amRNSTrading Statement
12th Jun 201210:30 amRNSDirector/PDMR Shareholding
8th Jun 20122:09 pmRNSDirector/PDMR Shareholding
7th Jun 20124:35 pmRNSDirector/PDMR Shareholding
25th May 201211:00 amRNSDirector Declaration
17th May 201212:22 pmRNSResult of AGM
17th May 201211:00 amRNSDirectorate Change
17th May 20127:00 amRNSInterim Management Statement
14th May 20123:47 pmRNSAnnual Information Update
17th Apr 20129:18 amRNSAnnual Financial Report
3rd Apr 20123:11 pmRNSDirector/PDMR Shareholding
2nd Apr 20127:00 amRNSMarl Site Operations
28th Mar 20125:15 pmRNSHolding(s) in Company
26th Mar 20127:00 amRNSDirector/PDMR Shareholding
23rd Mar 20127:00 amRNSDirectorate Change
19th Mar 20124:10 pmRNSDirector/PDMR Shareholding
16th Mar 20121:48 pmRNSDirector/PDMR Shareholding
16th Mar 20121:46 pmRNSDirector/PDMR Shareholding
16th Mar 20121:09 pmRNSDirector/PDMR Shareholding
14th Mar 20123:52 pmRNSDirector/PDMR Shareholding
14th Mar 20127:00 amRNSFinal Results
11th Jan 20127:00 amRNSTrading Update
9th Jan 201210:24 amRNSDirector/PDMR Shareholding
3rd Jan 20124:51 pmRNSDirector/PDMR Shareholding
1st Dec 20117:00 amRNSDisposal of Pharma Division
25th Nov 20117:00 amRNSDirectorate Change
10th Nov 20117:00 amRNSInterim Management Statement
1st Nov 20113:33 pmRNSHolding(s) in Company
31st Oct 201110:15 amRNSHolding(s) in Company
20th Oct 20112:42 pmRNSHolding(s) in Company
17th Oct 20118:20 amRNSAcquisition
28th Sep 20117:00 amRNSAnalyst and Investor Site Visit
5th Sep 20117:00 amRNSAppointment of Joint Broker
26th Aug 20117:00 amRNSHalf Yearly Report
10th Aug 20118:58 amRNSHolding(s) in Company
4th Aug 20119:02 amRNSBoard appointment
27th Jul 20111:12 pmRNSHolding(s) in Company
29th Jun 20114:46 pmRNSDirector/PDMR Shareholding
29th Jun 20114:44 pmRNSDirector/PDMR Shareholding
29th Jun 20112:17 pmRNSResult of EGM
22nd Jun 20113:59 pmRNSHolding(s) in Company
16th Jun 20114:39 pmRNSHolding(s) in Company
16th Jun 20114:37 pmRNSHolding(s) in Company
13th Jun 201111:14 amRNSNotice of EGM
9th Jun 201110:44 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.